AZD7325 Japan Multiple Ascending Dose (MAD) Study

NCT00945425 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

48

Enrollment

INDUSTRY

Sponsor class

Stopped Decided to stop development of this compound globally

Conditions

Healthy

Interventions

DRUG: AZD7325
DRUG: Placebo

Sponsor

AstraZeneca